
We reported last week that Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc. had filed suit in...
By C. Nichole Gifford and Seth Cockrum Comments are off
We reported last week that Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc. had filed suit in...
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By C. Nichole Gifford Comments are off
On March 21, 2017, Celltrion, Inc. (“Celltrion”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent Nos....
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By C. Nichole Gifford and Seth Cockrum Comments are off
Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc. (collectively “Plaintiffs”) filed a Complaint in the...
Tagged with: Amgen, District Court, dupilumab, Dupixent®, Immunex, Legal, Litigation, Regeneron, Sanofi
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By C. Nichole Gifford Comments are off
Hospira, Inc. (“Hospira”) filed a petition with the Patent Trial and Appeal Board (“PTAB”) on September 9, 2016, for inter partes...
Tagged with: Avastin®, bevacizumab, Genentech, Herceptin®, Hospira, IPR, Legal, News, PTAB, Roche, trastuzumab, USPTO
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By C. Nichole Gifford Comments are off
Celltrion, Inc. (“Celltrion”) filed three new petitions with the Patent Trial and Appeal Board (“PTAB”) on March 15, 2017 for inter...
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By C. Nichole Gifford Comments are off
Hospira, Inc. (“Hospira”) filed a petition with the Patent Trial and Appeal Board (“PTAB”) on September 16, 2016 for inter partes...
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By C. Nichole Gifford Comments are off
On March 10, 2017, the PTAB published a decision terminating the proceedings in IPR2016-1693 and IPR2016-1694 because the parties have...
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By C. Nichole Gifford Comments are off
Samsung Bioepsis UK Limited (“Samsung”), Biogen Idec Limited (“Biogen”), and Fujifilm Kyowa Kirin Biologic Company Limited...
Tagged with: AbbVie, adalimumab, Biogen, Fujifilm Biologics, Humira®, Invalidity, Legal, Litigation, News, Samsung Bioepsis
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By C. Nichole Gifford Comments are off
On March 2, 2017, the PTAB issued a decision denying Celltrion, Inc.’s (“Celltrion”) request for inter partes review (“IPR”) of...
ShareEmail, Linked In, Twitter, Facebook, Google Plus